Washington, D.C., (December 4, 2018) —MedStar Heart in partnership with CardioCell has been approved to conduct an investigational new drug clinical trial, called STEMVAD at MedStar Heart & Vascular Institute. The goal of this study is to determine whether stem cell therapy improves myocardial function in patients with severe heart failure. “Innovative therapies to improve heart function and outcomes of patients with advanced heart failure are sorely needed,” said Selma Mohammed, MD, PhD. Read more.
Recent Posts
- COVID-19: Results from the MedStar Health CDC Community Research Partnership (CRP) Study of COVID-19
MedStar Health has been conducting a large scale, multi-site Centers for Disease Control and Prevent... - COVID-19: MedStar Health Receives FDA Clearance to Trial an Oral Immunomodulatory Drug for COVID-19
Over the past year, our research team Dr. Thomas Fishbein, Dr. Khalid Khan and Dr. Alexander Kroemer... - COVID-19: MedStar Health Investigators Evaluate Substance Use Trends during the COVID-19 Pandemic
Collaborative research from MedStar Health Research Institute, MedStar Washington Hospital Center, G...
Contact
Eva Hochberger
Communications & Planning Manager
Phone: 301-560-2917
[email protected]